Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Palonosetron
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Avenacy Announces Launch of Palonosetron Hydrochloride Injection, USP in the U.S. Market
Details : Palonosetron HCl generic of Aloxi is a 5-HT3 receptor antagonist indicated as an antiemetic in adults for prevention of acute and delayed nausea and vomiting.
Product Name : Aloxi-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 22, 2024
Lead Product(s) : Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Netupitant,Palonosetron
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AKYNZEO (Netupitant) is the first and only 5-HT3 and NK1 receptor antagonist fixed combination approved in adults for the prevention of acute and delayed nausea and vomiting associated with cisplatin based highly emetogenic chemotherapy and moderately em...
Product Name : Akynzeo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2023
Lead Product(s) : Netupitant,Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Netupitant,Palonosetron
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Akynzeo is a combination of netupitant, a selective antagonist of human substance P/neurokinin 1 (NK-1) receptors and palonosetron, a 5-HT3 receptor antagonist with a strong binding affinity for this receptor. It is indicated for nausea due to cancer che...
Product Name : Akynzeo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 02, 2023
Lead Product(s) : Netupitant,Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Netupitant,Palonosetron
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Immedica Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Akynzeo (netupitant) is a 5-HT3 and NK1 receptor antagonist fixed combination approved in Europe in adults for the prevention of acute and delayed nausea and vomiting associated with cisplatin-based highly emetogenic chemotherapy and moderately emetogeni...
Product Name : Akynzeo
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 24, 2023
Lead Product(s) : Netupitant,Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Immedica Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Netupitant,Palonosetron
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Helsinn Announces Presentation On CINV Trial at European Society for Medical Oncology (ESMO) Asia
Details : Akynzeo is the first and only 5-HT3 and NK1 receptor antagonist fixed combination approved in adults for the prevention of acute and delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy.
Product Name : Akynzeo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 29, 2022
Lead Product(s) : Netupitant,Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Netupitant,Palonosetron
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Helsinn Advanced Synthesis
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the terms of the agreement, Farma Mondo will manage the commercialization of AKYNZEO® in Estonia and Latvia. AKYNZEO® hard capsules (combination of netupitant/palonosetron), for the treatment of chemotherapy-induced nausea and vomiting (CINV) in ...
Product Name : Akynzeo
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 28, 2022
Lead Product(s) : Netupitant,Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Helsinn Advanced Synthesis
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Palonosetron
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Helsinn Advanced Synthesis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details :
Product Name : Aloxi
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 10, 2021
Lead Product(s) : Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Helsinn Advanced Synthesis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Palonosetron
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Aloxi® has demonstrated its efficacy in delayed nausea and vomiting where available agents have hitherto provided insufficient effects.
Product Name : Aloxi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 15, 2020
Lead Product(s) : Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fosnetupitant Chloride,Palonosetron
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Helsinn Advanced Synthesis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Berlin-Chemie AG has been granted exclusive rights to import, distribute, promote, market and sell AKYNZEO® and ONICIT® in Russia and CIS region to manage chemotherapy-induced nausea and vomiting.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 27, 2020
Lead Product(s) : Fosnetupitant Chloride,Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Helsinn Advanced Synthesis
Deal Size : Undisclosed
Deal Type : Licensing Agreement